Nordeloz (Zoledronic Acid)

Zoledronic acid binds to bone mineral at sites of active remodeling. When osteoclasts attach to the drug‑coated bone, it is taken up and inhibits the enzyme farnesyl pyrophosphate synthase, leading to loss of prenylated proteins essential for osteoclast function. This triggers osteoclast apoptosis and markedly reduces bone resorption.

The dosing regimen for Nordeloz is determined by the prescribing clinician based on the specific indication, patient weight, renal function and other clinical factors. Healthcare professionals follow approved guidelines and adjust the infusion schedule according to individual patient needs.

The safety of zoledronic acid in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant. Physicians should discuss alternative options when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nordeloz. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nordeloz (zoledronic acid) is a highly potent, once‑yearly or once‑every‑few‑months intravenous bisphosphonate, offering greater convenience compared with oral agents that require weekly or daily dosing. Its potency allows for rapid and sustained suppression of bone turnover, but it also carries a distinct safety profile that requires monitoring of renal function and calcium levels.

Nordeloz should be stored at ambient temperature, below 25 °C, in its original packaging. The product must be protected from moisture and direct light to maintain stability. Do not refrigerate or freeze the solution unless specifically instructed by the manufacturer.

Nordeloz is given as an intravenous infusion over a short period, typically 15 minutes, under the supervision of a qualified healthcare professional. The infusion is performed in a clinical setting where vital signs can be monitored, and patients are observed for any acute reactions during and after the administration.

Serious adverse events include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, and life‑threatening hypersensitivity reactions such as anaphylaxis. Patients should be screened for dental health, renal function and calcium status before treatment, and monitored closely throughout therapy.

Nordeloz is contraindicated in patients with known hypersensitivity to zoledronic acid or any component of the formulation, in those with severe renal impairment (creatinine clearance < 30 mL/min), and in individuals with uncontrolled hypocalcaemia. Caution is also advised for patients with active dental infections or recent dental surgery.